{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:33:46Z","timestamp":1783384426567,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clgc.2021.08.004","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T11:44:00Z","timestamp":1630064640000},"page":"e395-e400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-7261","authenticated-orcid":false,"given":"Alixandra","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Tawagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-0563","authenticated-orcid":false,"given":"Nathan","family":"VanderVeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Matrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.08.004_bib0001","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JOP.2017.020909","article-title":"Renal medullary carcinoma: establishing standards in practice","volume":"13","author":"Beckermann","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clgc.2021.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/pbc.25592","article-title":"Renal medullary carcinoma and sickle cell trait: a systematic review","volume":"62","author":"Alvarez","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clgc.2021.08.004_bib0003","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.5489\/cuaj.2373","article-title":"Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature","volume":"9","author":"Iacovelli","year":"2015","journal-title":"Can Urol Assoc J\u00a0=\u00a0J l'Association des Urol du Canada"},{"key":"10.1016\/j.clgc.2021.08.004_bib0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/15384047.2014.972843","article-title":"Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression","volume":"16","author":"Lipkin","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clgc.2021.08.004_bib0005","doi-asserted-by":"crossref","first-page":"e26609","DOI":"10.1002\/pbc.26609","article-title":"Renal medullary carcinoma: a national analysis of 159 patients","volume":"64","author":"Ezekian","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clgc.2021.08.004_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-199501000-00001","article-title":"Renal medullary carcinoma. The seventh sickle cell nephropathy","volume":"19","author":"Davis","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2021.08.004_bib0007","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.5858\/arpa.2017-0492-RS","article-title":"Renal medullary carcinoma","volume":"143","author":"Elliott","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clgc.2021.08.004_bib0008","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bju.13705","article-title":"Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study","volume":"120","author":"Shah","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2021.08.004_bib0009","doi-asserted-by":"crossref","unstructured":"Wiele AJ, Surasi DS, Rao P, et\u00a0al. Efficacy and safety of bevacizumab plus erlotinib in patients with renal medullary carcinoma. Cancers (Basel). 2021;13:2170. doi:10.3390\/cancers13092170","DOI":"10.3390\/cancers13092170"},{"key":"10.1016\/j.clgc.2021.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2018.09.005","article-title":"Updated recommendations on the diagnosis, management, and clinical trial eligibility criteria for patients with renal medullary carcinoma","volume":"17","author":"Msaouel","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2021.08.004_bib0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.20517\/2572-8180.2017.23","article-title":"Metastatic renal medullary carcinoma: response to chemotherapy and unusual long survival","volume":"2","author":"Imtiaz","year":"2017","journal-title":"J Unexplored Med Data"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2021.08.004_bib0012","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.2021.39.6_suppl.324","article-title":"Efficacy of gemcitabine plus doxorubicin (Gem\u00a0+\u00a0Dox) in patients with renal medullary carcinoma (RMC)","volume":"39","author":"Wilson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.08.004_bib0013","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ccell.2020.04.002","article-title":"Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma","volume":"37","author":"Msaouel","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2021.08.004_bib0014","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature21064","article-title":"Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer","volume":"542","author":"Genovese","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2021.08.004_bib0015","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2019.01.006","article-title":"p53 is a master regulator of proteostasis in SMARCB1-deficient malignant rhabdoid tumors","volume":"35","author":"Carugo","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2021.08.004_bib0016","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2005.05.0344","article-title":"Medullary renal cell carcinoma and response to therapy with bortezomib","volume":"24","author":"Ronnen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2021.08.004_bib0017","doi-asserted-by":"crossref","first-page":"e20002","DOI":"10.1200\/jco.2011.29.15_suppl.e20002","article-title":"Active combination of platins\/paclitaxel\/gemcitabine\/bortezomib in a child with metastatic renal medullary carcinoma (RMC)","volume":"29","author":"Al-Rahawan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.08.004_bib0018","doi-asserted-by":"crossref","first-page":"e26402","DOI":"10.1002\/pbc.26402","article-title":"Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases","volume":"64","author":"Carden","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clgc.2021.08.004_bib0019","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1200\/JCO.2004.10.155","article-title":"Phase II trial of bortezomib for patients with advanced renal cell carcinoma","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.08.004_bib0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00280-008-0716-8","article-title":"A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors","volume":"63","author":"Dees","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2021.08.004_bib0021","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/pbc.22611","article-title":"Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma","volume":"55","author":"Walsh","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clgc.2021.08.004_bib0022","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.urology.2007.06.1124","article-title":"Renal medullary carcinoma: the Bronx experience","volume":"70","author":"Hakimi","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2021.08.004_bib0023","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1464-410X.2009.09139.x","article-title":"Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy","volume":"106","author":"Schaeffer","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2021.08.004_bib0024","unstructured":"Center MDAC. Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer. (ClinicalTrials.gov Identifier: NCT03587662)."},{"key":"10.1016\/j.clgc.2021.08.004_bib0025","doi-asserted-by":"crossref","first-page":"e987","DOI":"10.1016\/j.clgc.2017.04.012","article-title":"Genomic characterization of renal medullary carcinoma and treatment outcomes","volume":"15","author":"Carlo","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2021.08.004_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0206-1","article-title":"Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma","volume":"5","author":"Beckermann","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2021.08.004_bib0027","unstructured":"Center MDAC. Phase II trial of nivolumab plus ipilimumab in patients with renal medullary carcinoma. (ClinicalTrials.gov Identifier: NCT03274258) 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03274258"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321001610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321001610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:03Z","timestamp":1761564903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321001610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1558767321001610"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.08.004","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}